G1 Therapeutics, Inc.

FREE EMAIL WATCHDOG

Get free email notifications about news in G1 Therapeutics, Inc..

The service is free and you can unsubscribe at any time.

General | People (55) | Filings (47) | Investment rounds (8) | Stock | News

Industry: PHARMACEUTICAL PREPARATIONS [2834]

CIK Number: 0001560241
IRS Number: 263648180

G1 Therapeutics, Inc. is a publicly traded company

Trading symbol: GTHX

G1 Therapeutics, Inc. is on the market more than 5 years.

News

2017-06-12

Needham & Company Starts G1 Therapeutics (GTHX) at Buy; Unique and Best-in ...
StreetInsider.com
Needham & Company initiates coverage on G1 Therapeutics (NASDAQ: GTHX) with a Buy rating and a price target of $34.00.
Needham & Company LLC Initiates Coverage on G1 THERAPEUTICS (GTHX) - The Cerbat Gem
G1 THERAPEUTICS (GTHX) Coverage Initiated at Cowen and Company - BNB Daily (blog)

2017-06-12

Needham & Company Starts G1 Therapeutics (GTHX) at Buy
StreetInsider.com
Needham & Company initiates coverage on G1 Therapeutics (NASDAQ: GTHX) with a Buy rating and a price target of $34.00.
G1 Therapeutics (GTHX) Announces May 17th IPO - The Cerbat Gem

2017-05-30

G1 Therapeutics to Present Clinical Data on CDK4/6 Inhibitor Trilaciclib at ...
GlobeNewswire (press release)
RESEARCH TRIANGLE PARK, N.C., May 30, 2017 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a clinical-stage oncology company, today announced that Phase 1b data from the ongoing Phase 1b/2a study of its lead CDK4/6 inhibitor ...

2017-05-26

G1 THERAPEUTICS, INC. (NASDAQ:GTHX) Files An 8-K Departure of Directors or ...
Market Exclusive
G1 THERAPEUTICS, INC. (NASDAQ:GTHX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

2017-05-23

G1 Therapeutics Announces Closing of Initial Public Offering
GlobeNewswire (press release)
RESEARCH TRIANGLE PARK, N.C., May 23, 2017 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a clinical-stage oncology company, today announced the closing of its initial public offering of 7,781,564 shares of common stock at a public ...

2017-05-18

G1 Therapeutics makes Nasdaq debut
Triangle Business Journal
The company priced its initial public offering of 7 million shares of common stock at $15.00 per share, equating to proceeds of $105 million.

2017-05-17

G1 Therapeutics raises $105M in Nasdaq debut
News & Observer
Research Triangle Park-based biotechnology company G1 Therapeutics Inc. debuted as a publicly traded company on the Nasdaq Stock Market Wednesday raising $105 million in its initial public offering.
G1 Therapeutics Inc. Plans To Go Public In Its Early Stages - Seeking Alpha
Cancer biotech G1 Therapeutics prices upsized IPO at $15, the low end of the range - Nasdaq

G1 Therapeutics, Inc. address

79 T.W. ALEXANDER DRIVE
4501 RESEARCH COMMONS, SUITE 100
RESEARCH TRIANGLE PARK
27709

G1 Therapeutics, Inc. address

P. O. BOX # 110341
RESEARCH TRIANGLE PARK
27709

G1 Therapeutics, Inc. address

79 T.W. ALEXANDER DRIVE
4501 RESEARCH COMMONS, SUITE 100
RESEARCH TRIANGLE PARK
27709

Former name

Former name of this company was G-Zero Therapeutics, Inc., date of change: 2012-10-12.

Company jurisdiction

DELAWARE

Entity type

Corporation

Earliest known filing

October 2012

Latest known filing

June 2017

Company filings

SEC filings are a great source of information for companies including investments, company events, and all sorts of other information.

G1 Therapeutics, Inc. has 47 filings. View G1 Therapeutics, Inc. filings.

Latest company events

Investment Rounds

G1 Therapeutics, Inc. recieved 8 investments.

People

We have found 55 people related to G1 Therapeutics, Inc..

Similar companies

G1 Enterprises, LLC, G1 EXECUTION SERVICES, LLC, G10-Rosseau Special Situations Fund (US) LP, G14M2 HHC, L.L.C., G1R Florida, LLC, G1R Mass, LLC